Literature DB >> 11148434

Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk?

H Dormann1, S Krebs, U Muth-Selbach, M Criegee-Rieck, M Radespiel-Tröger, M Levy, E G Hahn, K Brune, H T Schneider.   

Abstract

BACKGROUND: It has been claimed that the risk of adverse drug reactions increases with age. However, only limited data exist for disease-group specific risks and none for patients with liver and gastrointestinal diseases. AIMS: To determine the incidence and characteristics of adverse drug reactions and the physicians' awareness of adverse drug reactions.
METHODS: During a 7-month period, a prospective survey of 532 male patients (158 aged 65 years or older; 30%) was conducted on a hepatogastroenterological ward of a tertiary-care university hospital, using intensive bedside and computer-assisted drug surveillance methods.
RESULTS: No difference was found in the overall rate of adverse drug reactions between older and younger patients (25.9% vs. 24.2%) during 6213 treatment days. However, a significantly higher risk for developing adverse drug reactions could be shown for the elderly with biliary tract diseases (P < 0.01). Independently of age, patients suffering from gastric ulcers, acute episodes of pancreatitis, cholangitis or inflammatory bowel diseases were at high risk of adverse drug reactions. Adverse drug reaction-associated mortality was encountered in four elderly and none of the younger patients. Secondary pharmacological effects and drug toxicity were the main types of adverse drug reactions for both age groups. Although 75.3% of the adverse drug reactions were predictable, only 37.5% of all adverse drug reactions were recognized by the staff physicians.
CONCLUSION: In hepatogastroenterological patients, advancing age was not associated with an overall increased risk of adverse drug reactions except for patients with biliary tract diseases. In the elderly, adverse drug reactions were more severe and carried higher mortality. Guidelines and educational programs should be developed to increase the awareness of adverse drug reactions and their prevention, especially in high risk patients and, thus, to improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148434     DOI: 10.1046/j.1365-2036.2001.00922.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Lack of awareness of community-acquired adverse drug reactions upon hospital admission : dimensions and consequences of a dilemma.

Authors:  Harald Dormann; Manfred Criegee-Rieck; Antje Neubert; Tobias Egger; Arnim Geise; Sabine Krebs; Thomas Schneider; Micha Levy; Eckhart Hahn; Kay Brune
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.

Authors:  Tobias Egger; Harald Dormann; Gabi Ahne; Andreas Pahl; Ulrich Runge; Tanya Azaz-Livshits; Antje Neubert; Manfred Criegee-Rieck; Karl G Gassmann; Kay Brune
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Evaluation of adverse drug reactions in medical intensive care units.

Authors:  Sojin Park; Yongwon In; Gee Young Suh; Kieho Sohn; Eunyoung Kim
Journal:  Eur J Clin Pharmacol       Date:  2012-06-07       Impact factor: 2.953

Review 4.  Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis.

Authors:  Tadele Mekuriya Yadesa; Freddy Eric Kitutu; Serawit Deyno; Patrick Engeu Ogwang; Robert Tamukong; Paul E Alele
Journal:  SAGE Open Med       Date:  2021-08-18

5.  Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals.

Authors:  Yurdaguel Zopf; Christina Rabe; Antje Neubert; Eckhart G Hahn; Harald Dormann
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 6.  Adverse drug reactions in elderly patients.

Authors:  P A Routledge; M S O'Mahony; K W Woodhouse
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

7.  Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting.

Authors:  Antoine Pariente; Dina Joseph-Reinette Sanctussy; Ghada Miremont-Salamé; Nicholas Moore; Françoise Haramburu; Annie Fourrier-Réglat
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

8.  Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel's View on Preventable Harm Associated with NSAID Therapy.

Authors:  Robert Taylor; Salma Lemtouni; Karen Weiss; Joseph V Pergolizzi
Journal:  Curr Gerontol Geriatr Res       Date:  2012-02-14

9.  Short-term mortality after perforated or bleeding peptic ulcer among elderly patients: a population-based cohort study.

Authors:  Steffen Christensen; Anders Riis; Mette Nørgaard; Henrik T Sørensen; Reimar W Thomsen
Journal:  BMC Geriatr       Date:  2007-04-17       Impact factor: 3.921

10.  Predictive factors for effectiveness and safety of enoxaparin for total knee arthroplasty in aged Japanese patients: a retrospective review.

Authors:  Akihiro Sonoda; Yuki Kondo; Yasuhiro Tsuneyoshi; Yoshitaka Iwashita; Shoji Nakao; Kazuhisa Ishida; Kentaro Oniki; Junji Saruwatari; Tetsumi Irie; Yoichi Ishitsuka
Journal:  J Pharm Health Care Sci       Date:  2017-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.